Login to Your Account

ODAC Recommends Accelerated Approval

Perjeta Poised to Blaze a New Trail in Neoadjuvant Breast Cancer Therapy

By Catherine Shaffer
Staff Writer

Friday, September 13, 2013
The FDA’s Oncologic Drugs Advisory Committee voted 13 - 1 Thursday to support approval of Genentech Inc.’s supplemental biologics license application for Perjeta (pertuzumab) in neoadjuvant (preoperative) treatment of breast cancer. The application is the first for a neoadjuvant indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription